Thyrocare

Docon retains a 51.02% stake in Thyrocare after selling part of its holding.[3] source: YourStory[4] source: The Hindu BusinessLine CNBC-TV18 reported Thyrocare's market capitalisation at ₹9,758.43 crore in August 2026.[5] source: CNBC-TV18

In September 2026, Business Standard reported that Thyrocare's GLP-1 Health Check packages, offering up to 81 tests, were available nationwide from ₹2,799.[6] source: Business Standard An Inc42 roundup that month covered Thyrocare's radiology exit, with a sale value of about ₹141.4 crore.[7] source: Inc42 In August 2026, API Holdings repaid ₹1,050 crore of term debt using Thyrocare stake-sale proceeds and internal accruals, which released the pledge on Docon's Thyrocare shares.[4] source: The Hindu BusinessLine The sale covered 1,57,69,696 Thyrocare shares, or 9.90% of paid-up equity.[4] source: The Hindu BusinessLine CNBC-TV18 reported that about 1.3 crore shares worth about ₹822 crore changed hands and that the promoter intends to retain at least 51%.[5] source: CNBC-TV18 Thyrocare's shares closed at ₹653 on 14 August 2026.[4] source: The Hindu BusinessLine

CNBC-TV18 reported that API Holdings may consider a PharmEasy listing or reverse merger into Thyrocare only after it becomes debt-free and profitable.[5] source: CNBC-TV18 Thyrocare founder Velumani backed keeping UPI free, Business Today reported in September 2026.[8] source: Business Today